CSIMarket
 
Amneal Pharmaceuticals Inc   (AMRX)
Other Ticker:  
 
 
Price: $5.5000 $0.11 2.041%
Day's High: $5.52 Week Perf: 2.23 %
Day's Low: $ 5.35 30 Day Perf: -5.5 %
Volume (M): 2,240 52 Wk High: $ 6.30
Volume (M$): $ 12,321 52 Wk Avg: $3.80
Open: $5.36 52 Wk Low: $1.24



 Market Capitalization (Millions $) 962
 Shares Outstanding (Millions) 175
 Employees 6,500
 Revenues (TTM) (Millions $) 2,394
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) 64
 Capital Exp. (TTM) (Millions $) 66

Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company was founded in 2005 by Chirag and Chintu Patel, and is headquartered in Bridgewater, New Jersey, United States.

Amneal has a broad portfolio of products that spans across various therapeutic areas, including CNS disorders, gastrointestinal disorders, cardiovascular diseases, and pain management. The company's products are distributed in more than 150 countries worldwide, through a combination of direct sales, strategic partnerships, and licensing agreements.

Amneal Pharmaceuticals has several manufacturing facilities that operate under strict quality control guidelines and adhere to international regulatory standards. The company's manufacturing facilities are located in the United States, India, Germany, the United Kingdom, and Ireland.

The company has a strong research and development (R&D) pipeline that focuses on developing novel pharmaceutical products using innovative delivery technologies. The R&D team consists of experienced scientists and researchers who work in state-of-the-art laboratories and collaborate with academic institutions and other pharmaceutical companies to develop new and innovative products.

Amneal Pharmaceuticals has received numerous awards and recognitions for its contribution to the pharmaceutical industry. In 2020, the company was named "Generics Company of the Year" by the Generic Pharmaceutical Association (GPhA) and ranked #331 in the Fortune 500 list.

The company's mission is to improve patient health by providing high-quality, affordable pharmaceutical products to people around the world. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program that supports community development, education, and environmental conservation initiatives.

In summary, Amneal Pharmaceuticals Inc. is a global pharmaceutical company that specializes in the development, manufacture, and distribution of high-quality generic and branded pharmaceutical products. The company has a broad portfolio of products that are distributed in more than 150 countries worldwide, and has a strong research and development pipeline that focuses on developing innovative pharmaceutical products. The company is committed to sustainability and ethical business practices, and has a strong corporate social responsibility program.


   Company Address: 400 Crossing Boulevard Bridgewater 8807 NJ
   Company Phone Number: 947-3120   Stock Exchange / Ticker: NASDAQ AMRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TEVA        0.6% 
• View Complete Report
   



Amneal Pharmaceuticals Inc

The company faces challenges in fourth quarter financial results, but reports revenue enhancement for full-year 2023


As an investor closely following the pharmaceutical industry, I have eagerly awaited the release of Amneal Pharmaceuticals Inc's fourth quarter and full-year 2023 financial results. The figures reveal a complex financial landscape for the company, with both positive and concerning trends.
Let's start with the less favorable aspects of the report. The fourth quarter of 2023 showcased an increase in loss per share for Amneal Pharmaceuticals Inc, rising to $-0.40 per share compared to $-0.03 in the same period a year prior. Additionally, the company's earnings per share fell from $0.06 in the previous financial reporting period. These figures indicate a challenging quarter for the company, marked by increased financial losses.

Product Service News

Amneal's Exclusive Licensing Agreement with Zambon Brings Promising Parkinson's Disease Treatment to Europe

Published Tue, Feb 27 2024 1:00 PM UTC

Amneal Pharmaceuticals, Inc. has recently entered into an exclusive licensing agreement with Zambon Biotech SA to bring a novel treatment for Parkinson's disease (PD) to the European Union, United Kingdom, and Switzerland. The licensing agreement covers the distribution and commercialization of IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsul...

Product Service News

Amneal Pharmaceuticals Resubmits IPX203 NDA to FDA, Transfers Stock Exchange Listing to Nasdaq, and Partners with BIAL for U.S. Licensing of ONGENTYS

Published Thu, Feb 8 2024 9:05 PM UTC

Amneal Pharma Resubmits New Drug Application for IPX203 to FDA and Announces Move to Nasdaq; Partners with BIAL for U.S. Licensing Agreement on ONGENTYSAmneal Pharmaceuticals, Inc. (Amneal), a leading global pharmaceutical company, has recently made significant announcements regarding its drug development, stock market listing, and strategic partnerships. In a press release ...

Product Service News

Amneal Pharmaceuticals Initiates Pioneering Step in Ophthalmic Healthcare and Parkinson's Treatment with Launch of Complex Generic and Exclusive Licensing

Published Wed, Jan 10 2024 1:00 PM UTC

In an exciting development for pharmaceutical science, Amneal Pharmaceuticals Inc. recently announced two significant moves that could potentially reshape specific areas in healthcare and treatment. Firstly, the company received approval for the launch of a generic version of Fluorometholone ophthalmic suspension. This product, conferred with 180 days of competitive generic ...

Product Service News

Revolutionizing Biotech: Amneal Pharmaceuticals Shines Bright on Nasdaq

Published Fri, Dec 15 2023 9:05 PM UTC

Amneal Pharmaceuticals Makes Historic Move to Nasdaq, Driving Growth and Innovation in Biotech Industry
Bridgewater, New Jersey - In a groundbreaking decision, Amneal Pharmaceuticals, Inc. (Amneal) (NYSE: AMRX) announced its plans to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Stock Market (Nasdaq). The move is expected to ta...






 

Amneal Pharmaceuticals Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Amneal Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Amneal Pharmaceuticals Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com